ClinicalTrials.gg
Not yet recruitingNCT07846839Updated Sep 29, 2026

Validation of MoCA-B and MoCA-Blind for Screening Cognitive Decline

An observational study in Neurocognitive Deficit, sponsored by Universidade Federal do Rio Grande do Norte. Not yet recruiting. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Universidade Federal do Rio Grande do Norte · Observational

How we know

Updated Sep 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
124
Ages
60 Years and older
Sex
All
01

Study summary

The objective of this observational study is to assess the efficacy of two neuropsychological tests (MoCA-B and MoCA-Blind) in detecting cognitive decline in older adults. The main questions it aims to answer are:

Can the results obtained by older adults on the MoCA-B distinguish between those with and without cognitive decline? Can the results obtained by older adults on the MoCA-Blind distinguish between those with and without cognitive decline?

Participants will be required to: 1. Complete a sociodemographic questionnaire; 2. Undergo a visual acuity test; 3. Complete the Pfeffer and IQCODE scales; and 4. Complete the MMSE, MoCA-B, and MoCA-Blind.

02

Conditions studied

  • Neurocognitive Deficit

Browse trials for

Keywords

  • neurocognitive déficit
  • MoCA-B
  • MoCA-Blind
  • neuropsychological assessment
  • visual impairment
03

In context

Vision Disorders

361 studies on the registry are indexed under Vision Disorders; 85 are open to participants now.

This study's planned enrollment of 124 is close to the median of 126 across 97 observational studies indexed under Vision Disorders.

Browse Vision Disorders studies →

Lead sponsor

Universidade Federal do Rio Grande do Norte is the lead sponsor of 86 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Older adults (60 years or older) with and without cognitive decline and with and without visual impairment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Older adults aged 60 and over;

Exclusion criteria

  • Participants under 60 years of age
  • Participants with a prior neuropsychological, neurological, or psychiatric diagnosis that could negatively influence assessment results, such as schizophrenia, stroke within the last three months, intellectual disability, etc
  • Participants with self-reported or diagnosed hearing impairment (hearing loss or deafness) that is not corrected by hearing aids.
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
124 participants (estimated)
Patient registry
No

Groups and cohorts

  • older adults with cognitive decline and without visual impairment
  • older adults without cognitive decline (healthy) and without visual impairment
  • older adults with cognitive decline and with visual impairment
  • older adults without cognitive decline and with visual impairment
06

What researchers measure

Primary outcomes

  1. Optimal cut-off score for the MoCA-B and MoCA-Blind

    The scores obtained by the participants (0 to 30) will be used to calculate the ROC curve and determine the optimal cutoff point (highest sensitivity and specificity) to distinguish between cognitive decline and healthy individuals.

    Time frame: Assessed at baseline (Day 0)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Mar 2027, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2026
First posted
Sep 29, 2026
StartEst.
Oct 2026
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07846839
Lead sponsor
Universidade Federal do Rio Grande do Norte
Collaborators
Federal University of São Paulo, Universidade Federal de Goias, Universidade Estadual de Goiás, Universidade Federal do Rio Grande (FURG)
Responsible party
Letícia Ellen Cunha Pereira (master's student, Universidade Federal do Rio Grande do Norte) — Principal investigator
First posted
Sep 29, 2026
Start date
Oct 2026 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Sep 29, 2026

Study contacts

Letícia C Pereira, Master's Student
Contact
leticiaellencp@gmail.com
+55 (84) 999104200

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion